Bioxyne Limited (AU:BXN)
ASX:BXN
BXN Stock Chart & Stats
AU$0.04
<AU$0.01(4.17%)
At close: 4:00 PM EST
AU$0.04
<AU$0.01(4.17%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.07
Previous CloseN/A
Volume631.90K
Average Volume (3M)4.35M
Market Cap
AU$147.51M
Enterprise ValueAU$143.30M
Total Cash (Recent Filing)AU$7.60M
Total Debt (Recent Filing)AU$7.43M
Price to Earnings (P/E)3.2
Beta1.55
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,269,326,400
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained 77% annual revenue growth reflects strong product demand and successful market penetration in regulated channels. Over the next 2-6 months this growth supports higher capacity utilization, improved operating leverage and provides recurring top-line momentum that underpins reinvestment in R&D and distribution.
Cash GenerationA dramatic FCF improvement (3473.2%) and solid cash conversion ratios indicate the business can generate real cash from operations. This durable improvement reduces reliance on external funding, supports capex and working capital needs, and increases resilience to short-term revenue volatility while enabling strategic investments.
Conservative Leverage & High ROEVery low leverage alongside a high ROE shows efficient use of shareholder capital and a conservative balance sheet. Structurally, this enhances financial flexibility, lowers insolvency risk during market stress, and allows the company to finance growth or pursue partnerships without immediate balance sheet strain.
Bears Say
Gross Margin PressureA 34.3% gross margin is modest for a specialty product business and limits the buffer against rising input, cultivation, or extraction costs. Over months this constrains the company’s ability to expand operating margins, fund marketing and product development, and compete on price without improving production efficiency.
Small Operating ScaleA very small headcount suggests limited internal bandwidth for scaling sales, regulatory management, manufacturing and quality assurance. Structurally this raises execution risk as growth requires rapid hiring, systems and process investments; operational bottlenecks could impair sustainable commercial expansion.
Regulatory ConcentrationConcentration in regulated medicinal cannabis markets exposes the business to licensing, compliance and policy risk that can shift over months. While regulation creates barriers to entry, regulatory changes, reimbursement dynamics or stricter controls could materially slow addressable market growth and constrain long-term revenue visibility.
Bioxyne Limited News
BXN FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.
What is Bioxyne Limited’s market cap?
Bioxyne Limited’s market cap is AU$147.51M.
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Aug 28, 2026 which is in 139 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Feb 25, 2026. The company reported AU$0.003 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.003.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 2,269,326,400 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0.003 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 15.385%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioxyne Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BXN Sentiment 83%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$90.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
200.00%
12-Months-Change
Fundamentals
Return on Equity
56.29%
Trailing 12-Months
Asset Growth
131.94%
Trailing 12-Months
Company Description
Bioxyne Limited
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing various functional foods and beauty products. Its products portfolio includes Progastrim for Gut and Immune Health; Progastrim plus Vitamin C for cold symptoms; and proTract for atopic dermatitis (eczema) for infants. The company provides its products online, as well as through wholesale and direct sales in the United States and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Technical Analysis
Wellnex Life Ltd
―
EVE Health Group Limited
―
Holista Colltech Limited
―
Clover Corporation Limited
―
Maggie Beer Holdings Ltd.
―
Options Prices
Currently, No data available
---